Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,069,060
  • Shares Outstanding, K 60,696
  • Annual Sales, $ 320 K
  • Annual Income, $ -404,730 K
  • 60-Month Beta 0.53
  • Price/Sales 12,633.90
  • Price/Cash Flow N/A
  • Price/Book 3.71
Trade ARNA with:

Options Overview

Details
  • Implied Volatility 46.08%
  • Historical Volatility 25.52%
  • IV Percentile 5%
  • IV Rank 6.54%
  • IV High 119.89% on 10/13/20
  • IV Low 40.91% on 03/22/21
  • Put/Call Vol Ratio 0.11
  • Today's Volume 167
  • Volume Avg (30-Day) 195
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 6,039
  • Open Int (30-Day) 8,491

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -2.21
  • Number of Estimates 4
  • High Estimate -2.17
  • Low Estimate -2.23
  • Prior Year -1.61
  • Growth Rate Est. (year over year) -37.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.90 +13.76%
on 06/08/21
68.57 -0.63%
on 06/21/21
+5.35 (+8.52%)
since 05/21/21
3-Month
59.55 +14.42%
on 05/13/21
77.58 -12.17%
on 03/22/21
-7.78 (-10.25%)
since 03/19/21
52-Week
59.55 +14.42%
on 05/13/21
90.19 -24.45%
on 11/04/20
+5.08 (+8.06%)
since 06/19/20

Most Recent Stories

More News
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an...

ARNA : 68.14 (+1.64%)
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years...

ARNA : 68.14 (+1.64%)
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

ARNA : 68.14 (+1.64%)
RGEN : 196.14 (-0.61%)
TECH : 440.21 (+1.92%)
KMDA : 5.79 (+0.87%)
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel

Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

ARNA : 68.14 (+1.64%)
RGEN : 196.14 (-0.61%)
BLPH : 4.02 (-1.71%)
AKRO : 29.48 (-1.57%)
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)

--- Currently no FDA approved therapies in the US for the treatment of EoE

ARNA : 68.14 (+1.64%)
Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels

PALM BEACH,  Fla., /PRNewswire/ --  The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing...

RTSL : 0.6000 (+3.90%)
JAZZ : 177.22 (-0.03%)
NTEC : 4.12 (-16.94%)
CARA : 14.34 (-1.44%)
ARNA : 68.14 (+1.64%)
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)

--- Currently no FDA approved therapies indicated for the treatment of cMVO

ARNA : 68.14 (+1.64%)
Why Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report?

Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ARNA : 68.14 (+1.64%)
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that as of 2021, Arena received an MSCI ESG Rating of "A." MSCI ESG Research provides MSCI ESG Ratings on global public and a few private companies...

ARNA : 68.14 (+1.64%)
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2021, the Compensation Committee of its Board of Directors granted to 22 new employees inducement stock options to purchase an...

ARNA : 68.14 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

3rd Resistance Point 71.35
2nd Resistance Point 69.96
1st Resistance Point 69.05
Last Price 68.14
1st Support Level 66.75
2nd Support Level 65.36
3rd Support Level 64.45

See More

52-Week High 90.19
Fibonacci 61.8% 78.49
Fibonacci 50% 74.87
Fibonacci 38.2% 71.25
Last Price 68.14
52-Week Low 59.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar